Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Kodiyanplakkal RP, Laplante JM, Westblade LF, Van Besien K, Salvatore M, St George K. Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient. Open Forum Infect Dis. 2019;6(12):ofz493.

Giunchi F, Fiorentino M, Loda M. The Metabolic Landscape of Prostate Cancer. Eur Urol Oncol. 2019;2(1):28-36.

Alvarez MJ, Yan P, Alpaugh ML, Bowden M, Sicinska E, Zhou CW, et al. Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'. Nat Genet. 2019;51(10):1427-1428.

Jessurun J, Cui I, Aristi-Urista G. Acute (gangrenous) esophageal necrosis (black esophagus). A rare form of injury with specific histologic features and diverse clinical associations with a common pathogenesis. Hum Pathol. 2019;87:44-50.

Zhao Z, Fan J, Hsu Y-, Lyon CJ, Ning B, Hu TY. Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application. Lab Chip. 2019;19(7):1114-1140.

Schwartz Z, Magro C, Nuovo G. The molecular-based differentiation of Heck's disease from its mimics including oral condyloma and white sponge nevus. Ann Diagn Pathol. 2019;43:151402.

McIntire PJ, Snow JT, Elsoukkary SS, Soong L, Sweeney J, Robinson BD, et al. Digital image analysis supports a nuclear-to-cytoplasmic ratio cutoff value below 0.7 for positive for high-grade urothelial carcinoma and suspicious for high-grade urothelial carcinoma in urine cytology specimens. Cancer Cytopathol. 2019;127(2):120-124.

Droesch C, Magro C. A comedonal variant of chronic cutaneous lupus erythematosus: Case report and literature review. JAAD Case Rep. 2019;5(9):801-805.

Hamid AA, Gray KP, Shaw G, Macconaill LE, Evan C, Bernard B, et al. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2019;76(1):89-97.

Bartlett NL, Wilson WH, Jung S-, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799.